Longitudinal Change in Myocardial Function and Clinical Parameters in Middle-Aged Subjects: A 3-Year Follow-up Study

Cho, Dong‐Hyuk; Joo, Hyung Joon; Kim, Mina; Kim, Hee‐Dong; Lim, Do–Sun; Park, Seong‐Mi

doi:10.4093/dmj.2020.0132

Cited by 3 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The residual volume in the present study increased by 52 mL/year, which is more than the expected 5–10% increase per decade [ 41 ], whereas the CO diffusing capacity declined by 0.29/year, which is less than the 0.35–0.49/year decline in women aged ≥ 50 years who had never been smokers, as reported elsewhere [ 42 ]. Likewise, the small decline in LVEF also appears to be -related to age, in keeping with longitudinal studies of patients with preserved ejection fraction [ 43 , 44 ].…”

Section: Discussionsupporting

confidence: 67%

Lung-Heart Outcomes and Mortality through the 2020 COVID-19 Pandemic in a Prospective Cohort of Breast Cancer Radiotherapy Patients

Vinh-Hung

Gorobets

Adriaenssens

et al. 2022

Cancers

View full text Add to dashboard Cite

We investigated lung-heart toxicity and mortality in 123 women with stage I-II breast cancer enrolled in 2007–2011 in a prospective trial of adjuvant radiotherapy (TomoBreast). We were concerned whether the COVID-19 pandemic affected the outcomes. All patients were analyzed as a single cohort. Lung-heart status was reverse-scored as freedom from adverse-events (fAE) on a 1–5 scale. Left ventricular ejection fraction (LVEF) and pulmonary function tests were untransformed. Statistical analyses applied least-square regression to calendar-year aggregated data. The significance of outliers was determined using the Dixon and the Grubbs corrected tests. At 12.0 years median follow-up, 103 patients remained alive; 10-years overall survival was 87.8%. In 2007–2019, 15 patients died, of whom 11 were cancer-related deaths. In 2020, five patients died, none of whom from cancer. fAE and lung-heart function declined gradually over a decade through 2019, but deteriorated markedly in 2020: fAE dipped significantly from 4.6–4.6 to 4.3–4.2; LVEF dipped to 58.4% versus the expected 60.3% (PDixon = 0.021, PGrubbs = 0.054); forced vital capacity dipped to 2.4 L vs. 2.6 L (PDixon = 0.043, PGrubbs = 0.181); carbon-monoxide diffusing capacity dipped to 12.6 mL/min/mmHg vs. 15.2 (PDixon = 0.008, PGrubbs = 0.006). In conclusion, excess non-cancer mortality was observed in 2020. Deaths in that year totaled one-third of the deaths in the previous decade, and revealed observable lung-heart deterioration.

show abstract

Section: Discussionsupporting

confidence: 67%

Lung-Heart Outcomes and Mortality through the 2020 COVID-19 Pandemic in a Prospective Cohort of Breast Cancer Radiotherapy Patients

Vinh-Hung

Gorobets

Adriaenssens

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…We also found the significant synergistic additive interaction regarding the risk of LVDD between women and MetS. The reason for the controversy may be the increased proportion of postmenopausal women 27 as menopause generally occurs around the age of 50. The loss of hormones protection may lead to the sharp increase in hypertension and dyslipidemia 28 .…”

Section: Discussionmentioning

confidence: 71%

Positive additive interaction effects of age, sex, obesity, and metabolic syndrome on left ventricular dysfunction

Zhou,

Ye,

Nie

et al. 2023

Journal of Diabetes

View full text Add to dashboard Cite

ObjectiveThis study aims to explore the association between metabolic syndrome (MetS) and left ventricular diastolic dysfunction (LVDD) and systolic dysfunction (LVSD), defined by impaired global longitudinal strain (GLS), and assess additive and multiplicative interactions among age, sex, obesity, and MetS regarding LVDD and LVSD.MethodsWe prospectively recruited 5503 participants from the China PEACE (Patient‐Centered Evaluative Assessment of Cardiac Events) Million Persons Project with complete echocardiography exam. Multivariable logistic models were used to calculate adjusted odds ratios to evaluate both additive and multiplicative interactions.ResultsThe mean age was 56.59 years; 59.4% were women, 46.7% had MetS, 26.6% had left ventricular hypertrophy, 46.3% had LVDD, and 12.50% had impaired GLS. Compared to the non‐MetS, the odds ratio (OR) of LVDD and impaired GLS in MetS were 1.40 (1.20–1.64) and 1.26 (1.03–1.54), respectively. For LVDD, relative excess risk due to additive interaction (RERI) for women and MetS, elderly and MetS, obesity and MetS were 0.76 (0.02–1.50), 35.65 (17.51–53.79), and 2.14 (0.66–3.62), respectively, thus suggesting additive interactions. For impaired GLS, RERI for obesity and MetS was 3.37 (0.50–6.24), thus suggesting additive interactions.ConclusionsThe MetS is independently associated with LVDD and impaired GLS. From the public health implications, prevention of MetS in women, elderly, and obese individuals might result in a greater reduction of LVDD and LVSD risk in cardiovascular high‐risk population.

show abstract

“…EAT was found to be linearly related to high-sensitivity C-reactive protein (hs-CRP) levels in asymptomatic individuals who underwent a cardiovascular health survey [40]. Additionally, EAT thickness was reported to be linearly associated with hs-CRP levels in middle-aged men with suspected metabolic syndrome [41].…”

Section: Pathophysiologic Mechanism Of Eat Inducing Myocardial Damagementioning

confidence: 99%

Epicardial Adipose Tissue and Heart Failure, Friend or Foe?

Cho,

Park

2024

Diabetes Metab J

Self Cite

View full text Add to dashboard Cite

Heart failure (HF) management guidelines recommend individualized assessments based on HF phenotypes. Adiposity is a known risk factor for HF. Recently, there has been an increased interest in organ-specific adiposity, specifically the role of the epicardial adipose tissue (EAT), in HF risk. EAT is easily assessable through various imaging modalities and is anatomically and functionally connected to the myocardium. In pathological conditions, EAT secretes inflammatory cytokines, releases excessive fatty acids, and increases mechanical load on the myocardium, resulting in myocardial remodeling. EAT plays a pathophysiological role in characterizing both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). In HFrEF, EAT volume is reduced, reflecting an impaired metabolic reservoir, whereas in HFpEF, the amount of EAT is associated with worse biomarker and hemodynamic profiles, indicating increased EAT activity. Studies have examined the possibility of therapeutically targeting EAT, and recent studies using sodium glucose cotransporter 2 inhibitors have shown potential in reducing EAT volume. However, further research is required to determine the clinical implications of reducing EAT activity in patients with HF.

show abstract

Longitudinal Change in Myocardial Function and Clinical Parameters in Middle-Aged Subjects: A 3-Year Follow-up Study

Cited by 3 publications

References 33 publications

Lung-Heart Outcomes and Mortality through the 2020 COVID-19 Pandemic in a Prospective Cohort of Breast Cancer Radiotherapy Patients

Lung-Heart Outcomes and Mortality through the 2020 COVID-19 Pandemic in a Prospective Cohort of Breast Cancer Radiotherapy Patients

Positive additive interaction effects of age, sex, obesity, and metabolic syndrome on left ventricular dysfunction

Epicardial Adipose Tissue and Heart Failure, Friend or Foe?

Contact Info

Product

Resources

About